PT - JOURNAL ARTICLE AU - Eyre, Max T AU - Burns, Rachel AU - Kirkby, Victoria AU - Smith, Catherine AU - Denaxas, Spiros AU - Nguyen, Vincent AU - Hayward, Andrew AU - Shallcross, Laura AU - Fragaszy, Ellen AU - Aldridge, Robert W TI - Impact of baseline cases of cough and fever on UK COVID-19 diagnostic testing rates: estimates from the Bug Watch community cohort study AID - 10.1101/2020.09.03.20187377 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.03.20187377 4099 - http://medrxiv.org/content/early/2020/09/05/2020.09.03.20187377.short 4100 - http://medrxiv.org/content/early/2020/09/05/2020.09.03.20187377.full AB - Background Diagnostic testing forms a major part of the UK’s response to the current COVID-19 pandemic with tests offered to people with a continuous cough, high temperature or anosmia. Testing capacity must be sufficient during the winter respiratory season when levels of cough and fever are high due to non-COVID-19 causes. This study aims to make predictions about the contribution of baseline cough or fever to future testing demand in the UK.Methods In this analysis of the Bug Watch prospective community cohort study, we estimated the incidence of cough or fever in England in 2018–2019. We then estimated the COVID-19 diagnostic testing rates required in the UK for baseline cough or fever cases for the period July 2020-June 2021. This was explored for different rates of the population requesting tests and four second wave scenarios and then compared to current national capacity.Results The baseline incidence of cough or fever in the UK is expected to rise rapidly from 154,554 (95%CI 103,083 – 231,725) cases per day in August 2020 to 250,708 (95%CI 181,095 – 347,080) in September, peaking at 444,660 (95%CI 353,084 – 559,988) in December. If 80% of baseline cough or fever cases request tests, average daily UK testing demand would exceed current capacity for five consecutive months (October 2020 to February 2021), with a peak demand of 147,240 (95%CI 73,978 – 239,502) tests per day above capacity in December 2020.Conclusions Our results show that current national COVID-19 testing capacity is likely to be exceeded by demand due to baseline cough and fever alone. This study highlights that the UK’s response to the COVID-19 pandemic must ensure that a high proportion of people with symptoms request tests, and that testing capacity is immediately scaled up to meet this high predicted demand.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was supported by Health Data Research UK (grant No. LOND1), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome Trust. This work is also supported by the Economic and Social Research Council, grant number ES/P008321/1, as part of the Preserving Antibiotics through Safe Stewardship (PASS) project. MTE is supported by an MRC studentship. SD is supported by an Alan Turing Fellowship. RWA is supported by a Wellcome Trust Clinical Research Career Development Fellowship (206602/Z/17/Z). The funders had no role in the design, analysis, interpretation, or writing.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was given ethical approval by the UCL Research Ethics Committee (ID 11813/001).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon publication, data and R script used for this analysis and production of figures will be made available on Dryad.